<DOC>
	<DOC>NCT00682630</DOC>
	<brief_summary>The objective of the study is to determine the bioequivalence of the combination of pyronaridine and artesunate (180:60mg) to-be-marketed tablet to the clinical trial reference tablet administered as a single total dose of 720:240 mg in healthy adults.</brief_summary>
	<brief_title>Bioequivalence of Pyronaridine Artesunate to-be-Marketed Tablet to the Clinical Trial Reference Tablet</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Pyronaridine</mesh_term>
	<criteria>1. Male or female subjects between the ages of 18 and 45 years with a body weight between 55 and 75 kg and a body mass index using Quetelet's Index weight (kg)/height2 (m2) between 1828 2. Signed and dated a written informed consent form before undergoing any study related activities, including discontinuation of any prohibited medications 3. Medically normal subjects with no significant abnormal findings at the screening physical examination as evaluated by the clinical investigator 4. Normal (or abnormal and clinically insignificant) laboratory values at screening 1. Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, acute QTc interval greater or equal to 450 mseconds), respiratory (including active tuberculosis), hepatic, renal, gastrointestinal, immunological (including active HIVAIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric or other abnormality (including head trauma) 2. Known history of hypersensitivity, allergic or adverse reactions to pyronaridine or artesunate or other artemisinins</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Malaria</keyword>
	<keyword>anti-malarial</keyword>
	<keyword>pyronaridine</keyword>
	<keyword>ACT</keyword>
</DOC>